# A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes

> **NCT00384956** · PHASE2 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 25 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT00384956
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2008-08
- **Final completion:** 2010-03
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2016-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00384956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00384956, "A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00384956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*